Tony’s career spans over 30 years of product development in several fields ranging from agricultural and food microbiology diagnostics to the life sciences and clinical diagnostics and across a wide number of diagnostic testing platforms including ELISA, Luminex, ECL Meso Scale, immuno-chromatographic, and time-resolved- and FRET-based assays for low- and high-throughput applications. He has led the assay development for a portfolio of several product targets including plant pathogens, genetically-modified organisms, pesticides and polyaromatic hydrocarbons in water and soil and AOAC-approved diagnostic kits for food microbiology (Listeria monocytogenes, E. coli O157:H7, and Salmonella spp.). He has developed several tests for clinical applications including CE-marked and FDA de novo tests for biomarkers of infectious diseases (alpha-defensin and human neutrophil elastase), a multiplexed microbial pathogen panel, and laboratory-developed tests for biomarkers of a number of arthritides (native septic, rheumatoid, and osteoarthritis), and biomarkers in support of drug clinical trials (e.g. oncology, hepatitis C, and Fabry disease). His corporate experience encompasses Agri-Diagnostics, Monsanto, Strategic Diagnostics, LabCorp, and more recently CD Diagnostics. He has co-authored numerous peer-reviewed publications, abstracts, presentations to scientific meetings, and patents in the field of diagnostics and assay development. Tony is a graduate of Rutgers University and The Ohio State University.